Category: Science Explained
Valerenic acid is the compound labs use to standardise valerian and the main suspect behind its proposed calming action. Here is what it does at the GABA-A receptor, why it is used as a quality marker, and why valerian's overall evidence stays weak.
Category: Science Decoded | Reading time: ~8 min | Level: Intermediate
Turn a valerian bottle around and you might see a phrase like standardised to 0.8 per cent valerenic acid. It looks like a mark of quality, and in one narrow sense it is. But that little percentage is carrying a lot of assumptions, and most people reading it never learn what valerenic acid actually is, what it is supposed to do, or the more awkward question of whether the herb it comes from works at all.
Valerenic acid is worth understanding precisely because it sits at the join between two very different things: a real quality-control tool and a mechanism that sounds more settled than the evidence supports. This is a plain account of what the compound is, why laboratories measure it, the receptor it is thought to act on, and the honest caveat that a marker on a label cannot rescue a herb whose clinical evidence is weak.
Valerenic acid is a compound found in the root of valerian, Valeriana officinalis, and one of the plant's characteristic constituents [1]. It has two jobs in practice. First, chemists use it as a marker: the substance they measure to describe how concentrated a valerian extract is and to keep one batch comparable to the next. Second, it is the compound most often proposed to explain valerian's traditional calming reputation [3].
The idea in one sentence: valerenic acid is both the yardstick for measuring valerian and the prime suspect for its supposed effect [1][3]. It is important not to collapse those two roles into each other. Being the marker a lab measures does not make valerenic acid the whole story of the plant, which contains many other compounds, and being the leading candidate for an effect does not mean that effect is proven.
The laboratory explanation for valerian's reputation centres on the GABA-A receptor. This is the main inhibitory receptor in the nervous system, the target through which the neurotransmitter GABA quietens nerve cell activity [3]. When activity at this receptor increases, neurons become less excitable, which is broadly why the receptor is associated with calm and sedation. Several sedative and anti-anxiety medicines act here.
Valerenic acid appears, in laboratory studies, to modulate this receptor [3]. That is the mechanistic basis for the calming claim, and it is a genuinely plausible pathway. But two honest qualifications matter. The effect observed in the laboratory looks mild and is characterised differently from pharmaceutical sedatives, and reaching the brain in a meaningful, consistent amount from a herbal extract is a further hurdle. A plausible mechanism explains the direction of a possible effect, not its size, and certainly not whether it shows up in a person trying to sleep.
A plant extract is not a clean single chemical. It is a mixture that shifts with the crop, the harvest, the part used and the processing, and a manufacturer needs some way to describe and control that variation. Measuring valerenic acid gives a fixed reference point, so a product can state a percentage and different batches can be kept comparable [1].
This is a real benefit, and it is worth respecting. A standardised extract is more consistent than an unstandardised powder, and consistency is exactly what you want if you are going to trial a herb properly. But standardisation is a quality tool, not an efficacy proof. The marker is a stand-in for the whole extract, and there is no reliable human evidence that pushing the valerenic acid figure higher reliably increases a clinical effect. Valerian's activity, if any, probably involves several compounds together rather than valerenic acid alone. So a higher percentage signals a concentrated, controlled extract, not a bigger benefit.
Here is the part the label will never carry. Standardising to a well-characterised marker is meaningless as evidence if the herb itself does not have a convincing effect, and valerian's evidence is weak.
Valerian has a long tradition of use and holds a European well-established-use registration for sleep and mild nervous tension, which is a stronger regulatory footing than many calming herbs have [1]. That is a genuine point in its favour. But the modern synthesis is unflattering. An umbrella review of systematic reviews, the highest tier of evidence synthesis available, found no clear evidence of efficacy for insomnia [4]. NCCIH describes the evidence as inconsistent [2]. A recurring pattern across the literature is telling: people's subjective ratings of their sleep sometimes improve, while objective measures do not move, which is the signature of expectation and ritual more than pharmacology [4].
None of this makes valerenic acid a fiction. It makes it a well-measured marker for a herb with a weak effect. Standardisation improves consistency; it cannot manufacture an efficacy the trials do not show. The trustworthy read is to value the marker for what it is, a quality signal, and to set expectations for valerian from the human evidence, which does not support a confident sleep claim.
If you are choosing a valerian product, a stated valerenic acid percentage is a modest point in its favour, because it means the manufacturer controls its batches. Prefer a standardised extract over an unlabelled powder for that reason. But do not read the marker as a potency promise, and do not expect a higher number to translate into a better night.
Set your expectations from the herb, not the label. Valerian is not an acute sleep aid; the European monograph itself notes a gradual onset and recommends continued use over roughly two to four weeks rather than a single bedtime dose [1]. If you trial it, give it that window, use objective as well as subjective judgement about whether it helps, and be prepared for the honest possibility that it does little. That is not cynicism; it is what the best evidence supports.
Valerian has a good tolerability record in trials, and its side effects are usually mild, such as drowsiness, stomach upset or vivid dreams [2]. Valerenic acid is a component of the extract rather than something typically taken alone.
Two cautions deserve prominence. There is a rare signal of liver injury linked to valerian, mostly when it is combined with other botanicals [2]. And valerian may add to the sedating effect of alcohol and of sedative medicines, so it should not be combined with them [2]. Abruptly stopping after long use may cause withdrawal-type symptoms.
Pregnant, breastfeeding, or on medication? Check with a healthcare professional first.
We would rather explain a marker than let it do marketing it has not earned. Valerenic acid is a legitimate quality tool and a plausible mechanism, and it is also a herb with weak clinical evidence, and holding both of those at once is the honest position.
Our Remedy Library grades herbs on the human evidence, not on how well they can be standardised, and Remy can talk you through what valerian's grade means before you buy. If you want the full picture on the herb itself, our piece on whether valerian root actually works goes through the trials in detail.
1. European Medicines Agency, HMPC (2016). European Union herbal monograph on Valeriana officinalis L., radix (EMA/HMPC/150848/2015). Regulatory monograph granting well-established-use status for sleep and mild nervous tension, with a gradual onset and a recommended two to four week course. 2. National Center for Complementary and Integrative Health (2020). Valerian. Government evidence synthesis describing inconsistent sleep evidence, mild side effects, a rare liver signal, and the caution against combining with alcohol or sedatives. 3. Bruni O, et al. (2021). Herbal remedies and their possible effect on the GABAergic system and sleep. Nutrients, PMID 33561990. Review noting that valerian may act via GABA receptors but that the mechanism in insomnia is not fully understood. 4. Valente V, et al. (2024). Efficacy and safety of valerian for insomnia: an umbrella review. European Neuropsychopharmacology, PMID 38359657. Umbrella review of systematic reviews concluding no clear evidence of efficacy for insomnia, with a good safety profile.
It is a naturally occurring compound in the root of valerian (Valeriana officinalis) and one of the plant's characteristic constituents. Chemists use it as a marker, meaning the substance they measure to describe how concentrated a valerian extract is and to keep batches consistent. It is also the compound most often proposed to explain valerian's traditional calming reputation, because in laboratory work it appears to act on a receptor involved in quietening nervous system activity. Being the marker does not make it the whole plant; valerian contains many other compounds too.
The leading explanation from laboratory studies is that valerenic acid modulates the GABA-A receptor, the main inhibitory or calming receptor in the brain. Substances that enhance activity at this receptor tend to reduce nervous system excitability. This is the same broad target that some sedative medicines act on, though valerenic acid's effect appears far milder and is characterised differently. The important honesty here is that this is a mechanism observed largely in the laboratory; showing a plausible pathway is not the same as proving a meaningful effect in people.
Because a plant extract is a mixture that varies with the crop, the harvest and the processing, and a manufacturer needs a way to describe and control that variation. Measuring valerenic acid gives a consistent reference point, so a product can state a percentage and different batches can be kept comparable. It is a quality-control tool. Standardising to a marker improves consistency, but it does not by itself prove the product is effective, because the marker is a stand-in for the whole extract, not a guaranteed measure of benefit.
Not in any proven way. A higher valerenic acid content tells you the extract is more concentrated by that measure, which helps with consistency, but there is no reliable human evidence that increasing valerenic acid reliably increases a clinical effect. Valerian's activity, if any, likely involves several compounds acting together rather than valerenic acid alone. So a higher marker figure is a reasonable sign of a concentrated, controlled extract, not a promise of a bigger benefit. Judge the product on its standardisation and tolerability, not on the marker number as a potency guarantee.
The honest answer is no, not to a confident standard. Valerian has a long tradition of use and holds a European well-established-use registration for sleep and mild nervous tension, but the modern evidence synthesis is unflattering. An umbrella review of systematic reviews found no clear evidence of efficacy for insomnia, and a recurring pattern is that people's subjective ratings sometimes improve while objective sleep measures do not. Valerian is best understood as a safe herb with a weak and inconsistent effect, not a settled sleep treatment.
Valerian as a whole has a good tolerability record in trials, with side effects that are usually mild, such as drowsiness or stomach upset. Valerenic acid is a component of that extract rather than something typically taken in isolation. There is a rare signal of liver injury linked to valerian, mostly when combined with other botanicals, and valerian may add to the effect of alcohol and sedatives, so it should not be combined with them. As with any herb, pregnancy, breastfeeding and existing medication are reasons to check with a clinician first.
It is the main inhibitory receptor in the nervous system, the target through which the neurotransmitter GABA reduces the activity of nerve cells. When GABA binds, it makes neurons less likely to fire, which is why activity at this receptor is associated with calming and sedation. Several sedative and anti-anxiety medicines act here. Valerenic acid is proposed to modulate this receptor, which is the mechanistic basis for valerian's calming reputation, though a laboratory mechanism does not by itself establish a clinical effect.
It is a modest point in its favour, but not a decisive one. A stated valerenic acid percentage means the product is standardised, which is a genuine quality signal that the manufacturer controls its batches. What it does not tell you is whether the product will help you sleep, because valerian's overall evidence is weak and there is no proven link between more marker and more effect. Treat the percentage as a sign of a controlled extract, then set realistic expectations about valerian itself.
Because acting on a receptor and acting on it strongly are very different things. Valerenic acid appears to modulate the GABA-A receptor gently and in a different way from pharmaceutical sedatives, and it reaches the brain in far smaller, less consistent amounts from a herbal extract. The receptor being shared explains the direction of the proposed effect, not its size. This is exactly why valerian's trial results are mild and inconsistent rather than reliably sedating, and why it is described as a weak effect.
A defined marker compound is reassuring for quality control, but it is not the same as proven efficacy, and it is easy to conflate the two. Having a measurable marker lets manufacturers standardise, which is good. It does not upgrade the clinical evidence, which for valerian remains weak. The trustworthy position is to value the standardisation for consistency while judging the herb's usefulness on the human trials, which do not support a confident sleep claim.